A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol

BMC Infectious Diseases

Dietrich Mack²  Ceri J Phillips²  Sue Plummer⁴  Michael B Gravenor²  Way Yee Cheung²  Alwyn Foden⁶  Helga Brown⁶  Anjan Dhar⁶  Wyn Harris¹  Caroline Bradley⁶  Kathie Wareham⁵  Stephen J Allen³ 

[1] Abertawe Bro Morgannwg University Hospital Board, One Talbot Gateway, Baglan Energy Park, Baglan, Port Talbot SA12 7BR, UK;Swansea University, Singleton Park, Swansea, SA2 8PP, UK;The College of Medicine, Swansea University, Room 314, Grove Building, Singleton Park, Swansea SA2 8PP, UK;Obsidian Research Limited, Unit 2 Christchurch Road, Baglan Industrial Park, Port Talbot, West Glamorgan SA12 7BZ, UK;Clinical Research Unit, Morriston Hospital, Swansea SA6 6NL, UK;County Durham and Darlington NHS Foundation Trust, Darlington Memorial Hospital, Hollyhurst Road, Darlington, County Durham DL3 6HX, UK

关键词: Hospital in-patient;    Elderly;    Clostridium difficile diarrhoea;    Antibiotic associated diarrhoea;    Antibiotic;    Bifidobacteria;    Lactobacilli;    Probiotic;   

Others  :  1175383
DOI  :  10.1186/1471-2334-12-108

 received in 2012-02-08, accepted in 2012-04-06,  发布年份 2012

【 摘 要 】

Background

Antibiotic associated diarrhoea complicates 5–39% of courses of antibiotic treatment. Major risk factors are increased age and admission to hospital. Of particular importance is C. difficile associated diarrhoea which occurs in about 4% of antibiotic courses and may result in severe illness, death and high healthcare costs. The emergence of the more virulent 027 strain of C. difficile has further heightened concerns. Probiotics may prevent antibiotic associated diarrhoea by several mechanisms including colonization resistance through maintaining a healthy gut flora.

Methods

This study aims to test the hypothesis that administration of a probiotic comprising two strains of lactobacilli and two strains of bifidobacteria alongside antibiotic treatment prevents antibiotic associated diarrhoea. We have designed a prospective, parallel group trial where people aged 65 years or more admitted to hospital and receiving one or more antibiotics are randomly allocated to receive either one capsule of the probiotic or a matching placebo daily for 21 days. The primary outcomes are the frequency of antibiotic associated and C. difficile diarrhoea during 8–12 weeks follow-up. To directly inform routine clinical practice, we will recruit a sufficient number of patients to demonstrate a 50% reduction in the frequency of C. difficile diarrhoea with a power of 80%. To maximize the generalizability of our findings and in view of the well-established safety record of probiotics, we will recruit a broad range of medical and surgical in-patients from two different health regions within the UK.

Discussion

Antibiotic associated diarrhoea constitutes a significant health burden. In particular, current measures to prevent and control C. difficile diarrhoea are expensive and disrupt clinical care. This trial may have considerable significance for the prevention of antibiotic associated diarrhoea in hospitals.

Trial registration

International Standard Randomised Controlled Trial Number Register ISRCTN70017204.

【 授权许可】

   
2012 Allen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Bartlett JG: Antibiotic-associated diarrhoea. N Engl J Med 2002, 346:334-339.
• [2]McFarland LV: Epidemiology, risk factors and treatment for antibiotic-associated diarrhoea. Dig Dis 1998, 16:292-307.
• [3]Viswanathan VK, Mallozzi MJ, Vedantam G: Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes 2010, 1:234-242.
• [4]Cartman ST, Heap JT, Kuehne SA, Cockayne A, Minton NP: The emergence of “hypervirulence” in Clostridium difficile. Int J Med Microbiol 2010, 300:387-395.
• [5]O’Brien JA, Lahue BJ, Caro JJ, Davidson DM: The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007, 28:1219-1227.
• [6]Dubberke ER, Wertheimer AI: Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009, 30:57-66.
• [7]Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ, ECDIS Study Group: Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63-73.
• [8]Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G: Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989, 96:981-988.
• [9]Pant C, Madonia P, Minocha A: Does PPI therapy predispose to Clostridium difficile infection? Nat Rev Gastroenterol Hepatol 2009, 6:555-557.
• [10]Dial S, Delaney JA, Schneider V, Suissa S: Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006, 175:745-748.
• [11]Hogenauer C, Hammer HF, Krejs GJ, Reisinger EC: Mechanisms and management of antibiotic-associated diarrhoea. Clin Infect Dis 1998, 27:702-710.
• [12]Gorkiewicz G: Nosocomial and antibiotic-associated diarrhoea caused by organisms other than Clostridium difficile. Int J Antimicrob Agents 2009, 33(Suppl 1):S37-S41.
• [13]Bergogne-Bérézin E: Treatment and prevention of antibiotic associated diarrhoea. Int J Antimicrob Agents 2000, 16:521-526.
• [14]Department of Health and Health Protection Agency: Clostridium difficile infection: How to deal with the problem. Best Practice Guidelines, Department of Health, London; 2008.
• [15]Lawley TD, Croucher NJ, Yu L, Clare S, Sebaihia M, Goulding D, Pickard DJ, Parkhill J, Choudhary J, Dougan G: Proteomic and genomic characterization of highly infectious Clostridium difficile 630 spores. J Bacteriol 2009, 191:5377-5386.
• [16]Dubberke ER, Haslam DB, Lanzas C, Bobo LD, Burnham CA, Gröhn YT, Tarr PI: The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge. Zoonoses Public Health 2011, 58:4-20.
• [17]Joint FAO/WHO Expert Consultation: Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Food and Agriculture Organization of the United Nations and World Health Organization; 2001. [ftp://ftp.fao.org./es/esn/food/wgreport2.pdf webcite]
• [18]McFarland LV: Meta-analysis of probiotics for the prevention of antibiotic associated diarrhoea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006, 101:812-822.
• [19]Plummer S, Weaver MA, Harris JC, Dee P, Hunter J: Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004, 7:59-62.
• [20]Thomas MR, Litin SC, Osmon DR, Corr AP, Weaver AL, Lohse CM: Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc 2001, 76:883-889.
• [21]Allen SJ: Probiotics in the prevention of antibiotic-associated diarrhoea. European Gastroenterology & Hepatology Reviewin press
• [22]Psaradellis E, Sampalis J: Efficacy of BIO K + CL1285® in the reduction of antibiotic associated diarrhea – a placebo controlled double-blind randomized, multi-center study. Arch Med Sci 2010, 6:56-64.
• [23]Sanders ME, Akkermans LM, Haller D, Hammerman C, Heimbach J, Hörmannsperger G, Huys G, Levy DD, Lutgendorff F, Mack D, Phothirath P, Solano-Aguilar G, Vaughan E: Safety assessment of probiotics for human use. Gut Microbes 2010, 1:164-185.
• [24]Southern California Evidence-based Practice Center, Santa Monica, CA, USA: Safety of Probiotics to Reduce Risk and Prevent or Treat Disease. Evidence Report/Technology Assessment Number 200; 2010. http://www.ahrq.gov/downloads/pub/evidence/pdf/probiotics/probiotics.pdf webcite
• [25]Hickson M: Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol 2011, 4:185-197.
• [26]Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG, Dutch Acute Pancreatitis Study Group: Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:651-659.
• [27]International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guidelines for Good Clinical Practice: . 1996. http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html webcite
• [28]McFarland LV: Evidence-based review of probiotics for antibiotic-associated diarrhoea and Clostridium difficile infections. Anaerobe 2009, 15:274-280.
• [29]Lewis SJ, Heaton KW: Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997, 32:920-924.
• [30]Planche T, Aghaizu A, Holliman R, Riley P, Poloniecki J, Breathnach A, Krishna S: Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008, 8:777-784.
• [31]Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G: Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 2001, 5:1-56.
• [32]Iglesais CP, Birks YF, Torgerson DJ: Improving the measurement of quality of life in older people: the York SF-12. Q J Med 2001, 94:695-698.
• [33]Wolvers D, Antoine JM, Myllyluoma E, Schrezenmeir J, Szajewska H, Rijkers GT: Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics. J Nutr 2010, 140:698-712S.
• [34]Rijkers GT, Bengmark S, Enck P, Haller D, Herz U, Kalliomaki M, Kudo S, Lenoir-Wijnkoop I, Mercenier A, Myllyluoma E, Rabot S, Rafter J, Szajewska H, Watzl B, Wells J, Wolvers D, Antoine JM: Guidance for substantiating the evidence for beneficial effects of probiotics: current status and recommendations for future research. J Nutr 2010, 140:671-676S.